Mesoblast LTD balance sheet

At the end of fiscal 2026, Mesoblast LTD had total assets of $773m, total liabilities of $205m and shareholders' equity of $568m. It held $103m in cash against $130m of debt: net debt of $26.9m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Mesoblast LTD: balance sheet, annual
Fiscal year	2016Jun 2016	2017Jun 2017	2018Jun 2018	2019Jun 2019	2020Jun 2020	2021Jun 2021	2022Jun 2022	2023Jun 2023	2024Jun 2024	2025Jun 2025	2026Jun 2026
Cash and equivalents	81	46	38	50	129	137	60	71	63	162	103
Receivables	—	4	50	4	2	5	4	7	21	15	58
Inventory	—	—	—	—	—	—	—	—	0	22	28
Total current assets	—	64	101	63	137	148	70	82	86	204	197
Total assets	—	656	692	652	734	745	662	669	669	785	773
Total current liabilities	—	37	24	44	90	94	51	42	73	103	81
Short-term debt	—	—	—	28	65	53	10	12	28	108	21
Long-term debt	—	—	59	67	57	41	92	103	100	68	109
Total debt	0	0	59	95	122	147	102	115	128	176	130
Total liabilities	—	139	146	171	184	163	165	168	189	187	205
Shareholders' equity	528	517	546	481	549	581	497	502	480	597	568
Net debt (negative = net cash)	−81	−46	22	45	−7	11	41	43	65	14	27

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: MESO vs RCUS MESO vs SPRY AGEN vs MESO

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Mesoblast LTD's SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Mesoblast LTD.